Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study

BACKGROUND: Current anemia therapies for patients with non–dialysis-dependent CKD may require injection and medical visits. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates erythropoiesis and improves iron homeostasis. METHODS: In this double-blind phase 3 study,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Soc Nephrol
Main Authors: Fishbane, Steven, El-Shahawy, Mohamed A., Pecoits-Filho, Roberto, Van, Bui Pham, Houser, Mark T., Frison, Lars, Little, Dustin J., Guzman, Nicolas J., Pergola, Pablo E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Nephrology 2021
Assuntos:
Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7920165/
https://ncbi.nlm.nih.gov/pubmed/33568383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2020081150
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados